Multiple immune system targets in the tumor microenvironment (SV-101) (SV-101 targets)

SV-101 is a proprietary therapeutic vaccine candidate developed by SiaVax that targets multiple undisclosed components within the tumor microenvironment (TME) (SiaVax Inc., 2023). Designed to treat advanced solid tumors, SV-101 utilizes a multi-antigen approach to stimulate a robust and diverse immune response, aiming to overcome the immunosuppressive barriers typically found in the TME (ClinicalTrials.gov, NCT04101331). By targeting several pathways or antigens simultaneously, the therapy seeks to minimize the risk of tumor escape and provide a more durable clinical benefit than single-target immunotherapies (AdisInsight, 2022). The exact molecular composition and specific targets of the SV-101 formulation remain proprietary, but its biological activity is centered on the activation of cytotoxic T lymphocytes and the modulation of the local immune landscape to favor anti-tumor activity (SiaVax, 2023). It is currently undergoing clinical evaluation to determine its safety profile and therapeutic potential in patients with various solid malignancies (ClinicalTrials.gov, 2023).

Other names

SV-101 targetsSiaVax SV-101 targetsMulti-antigen peptide vaccine targetsTumor microenvironment targets (SV-101)

SV-101 is a multi-antigen therapeutic vaccine designed to stimulate a broad immune response against various components of the tumor microenvironment, including tumor-associated antigens and potentially other immune-modulating factors.